Navigation Links
RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement
Date:9/3/2014

ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it received a payment of $1 million, representing the last tranche of a $2.5 million product license and securities purchase agreement with G-treeBNT Co., Ltd, to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S.  G-treeBNT purchased 8,333,333 shares of common stock at $0.12 per share and retains an option until January 31, 2015 to purchase additional common stock for $825,000 at $0.15 per share. The licensing and securities purchase agreements have previously been filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2014.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the development and potential future commercialization of RGN-137 and RGN-259, and possible future milestone payments or exercise of G-treeBNT's equity option.  Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can also be no assurance that any license agreement or product development program undertaken by RegeneRx or its licensees will be commercially successful. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

 


'/>"/>
SOURCE RegeneRx Biopharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology
2. New ROSA® WET®-S5 Aflatoxin Quantitative Test Receives USDA-GIPSA Approval
3. NEOMED Receives $12 Million from Federal Government
4. UT Arlington receives Walmart, Walmart Foundation innovation grant
5. Neumedicines Receives Award of $14 Million from BARDA for Continued Development of HemaMax™ as a Medical Countermeasure to Acute Radiation Exposure
6. Advanced Cell Diagnostics Receives ISO 13485:2003 Certification
7. Rebiotix Inc. Receives $25M for Series B Funding
8. Orexigen Receives CHMP Day 180 List of Outstanding Issues
9. UT Dallas professor receives Engineer of the Year award
10. Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology
11. Young Moscovite Researcher Receives this Years "Basel Declaration Award for Education in Animal Research"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 23, 2017 , ... The Academy of Model Aeronautics (AMA), ... Association (UAA), the unifying voice for collegiate aviation education, are launching a joint ... and success through a STEM-based education platform. , Much like the program currently ...
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, an innovation leader ... & Technologien GmbH, thereby expanding its product portfolio to include allergy and food ... asthma, atopic eczema or a food allergy. Allergies are escalating to epidemic proportions ...
(Date:6/22/2017)... Linda, Ca (PRWEB) , ... June 22, 2017 , ... ... worldwide. It took 20 years until the first data on cross-contamination of human cell ... lines has been an increasing issue in cell culture labs and is associated with ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found a biomarker ... Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding ... men. ”The logical next step, in my estimation, was to scientifically track the evidence ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):